Products & Services
News & Features
Join Our Community

h-lab.jpg

All Products & Services

Research Use Only (RUO)

CE-Marked Assays

View all products

Relevant Publications

 

2015 Product Catalog!

Request our 2015 product catalog

 

Wall Charts

Request a complimentary copy:

Hematologic Malignancy Testing Algorithm

Clonality Testing Strategy

 

Notice: Acute Myeloid Leukemia (AML) The FDA has made it clear that a FLT3 companion diagnostic is required for approval of any FLT3-targeted or FLT3-stratified therapy. LabPMM is the only clinical laboratory with access to the patents required to develop and offer a FLT3 companion diagnostic for worldwide use.


Personalized Medicine & IVS
Invivoscribe is a leading provider of clinically-validated CE-marked in vitro diagnostic products. Through our subsidiary, LabPMM, we provide worldwide access to molecular biomarker testing, which enables pharmaceutical companies to bring to the market new targeted treatments, and allows physicians to better determine optimal treatment for their patients.

Research & Biotechnology
Development & Partnering
Companion Diagnostics

LymphoTrack® IGH Somatic Hypermutation Assay for the MiSeq - Now available!

This assay includes a leader sequence primer that targets the entire IGHV gene and allows for the easy determination of SHM in clonal sequences using our LymphoTrack software package. Contact us for more information.


Thanks to everyone who attended Invivoscribe and Genection's workshops at AMP 2014! 

For those unable to attend, look forward to our forthcoming video summaries of both workshops: The MyAML™ Panel: Comprehensive Stratification of AML and Clonality Assessment and Monitoring Using LymphoTrack® Next-Generation Sequencing Assays!

 

LT-Assays-logo-2014-09.png

New NGS LymphoTrack® Assays!

The popular Next-Generation Sequencing-based LymphoTrack® portfolio has been expanded to include assays for the detection of IGH Somatic Hypermutation on the Ion PGM™ as well as a suite of assays which allow testing of TRG and IGH simultaneously in a single run on the MiSeq® or the Ion PGM. These assays were all designed for easy integration into a laboratory workflow and include bioinformatics software that allows for easy and streamlined data analysis. Using these assays, both the DNA sequences and frequency distributions of B- and T-cell rearrangements can be obtained. Contact us for more information.

 

LymphoTrack® Assays for the Ion PGM™ - Now available!

The popular Next-Generation Sequencing-based LymphoTrack® portfolio has been expanded beyond our current MiSeq formatted product line to include assays for TRG and IGH on the Ion PGM™. These assays were designed for easy integration into the laboratory workflow, and include a bioinformatics software that allows for simple and streamlined data analysis providing both DNA sequences and frequency distributions of B- and T-cell rearrangements. Contact us for more information.

 

View a video of our AMP 2013 Workshop!

We have posted a condensed version of our AMP workshop entitled Clonality Testing by Next-Generation Sequencing: Latest Developments from the New Frontier. This talk was given to a capacity audience in Phoenix, AZ in November 2013, and now you can enjoy highlights at your own convenience. Click here to view.

 

LymphoTrack® IGH Assay Launched

Invivoscribe has expanded its portfolio of next-generation sequencing (NGS) products with the introduction of the LymphoTrack® IGH Assay (for MiSeq platform). This assay provides unprecedented levels of information in the form of frequency distributions and DNA sequences of rearranged IGH genes. Click here for more information. Contact us to learn more.

 

In the News

We are excited to announce that LabPMM®, our subsidiary reference laboratories in the US and the EU, now offer the only standardized, internationally harmonized and licensed FLT3 Signal Ratio Assay.

Our FLT3 signal ratio (SR) assay tests for both ITD and TKD mutations, providing signal ratios for ITD mutations by comparing the signal intensity of the mutant and wild type amplicon products.

 

CAP Today

The Feature Story in the May 2013 issue of CAP Today titled: “Molecular clonality testing for lymphoma” highlights the benefits of PCR-based B and T cell clonality assays from Invivoscribe. Click here to view the article.

 

LabPMM and New York

LabPMM is happy to announce that we have received our New York state clinical lab license. Please contact us with any questions.

 

Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire Clinically-Actionable Genetic Menu.

Click here to learn more about Genection. 

 

January 8, 2014

Invivoscribe embraces the value of constant process improvement

 

July 16, 2013 Marketwired

Invivoscribe FLT3 Method Patent Claims Upheld 

 

June 19, 2013 Marketwired
Invivoscribe FLT3 Testing Patents Strengthened by Supreme Court Ruling

 

View all News

 

 h-fb.gif  h-twitter.gif  h-newsvine.gif  
 
Invivoscribe Companies

h-labPMM-logo.gif

genection-logo-ivsweb.gif

h-amlalliance.gif

h-ivs-sarl.gif

 

Meetings and Conferences

 

ASCO_log.jpg May 29-June 2, 2015

2015 ASCO Annual Meeting

Chicago, IL, USA.     

 

EHA_logo.jpg June 11-14, 2015
20th Congress of EHA.

Vienna, Austria.     

  

   

View all Events

 

 

 

 

 

 

ISO-FM-599728.png 

 

 

we-self-certify-150x15-f01.gif
SafeHarborLogo-168x69.png

web design by specto design